London And Palo Alto
LONDON and PALO ALTO, California, February 8 - Silence Therapeutics plc (AIM: SLN) today announced that the United
States Patent and Trademark Office (USPTO) has issued the company a notice of
allowance on a patent application directed to methods of treatment using a
high-value therapeutic target in the area of oncology.
LONDON and PALO ALTO, California, February 5 - Silence Therapeutics plc (AIM: SLN) today announced that Philip Haworth,
Ph.D., chief executive officer, will deliver a corporate overview and
business update at the 12th Annual BIO CEO & Investor Conference.
